|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
JAK2V617F mutation in patients with portal vein thrombosis.
|
18343999 |
2008 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
JAK2(V617F) is variably associated with thrombosis and, more consistently, with elevations in blood cell counts.
|
19176988 |
2008 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
This study adds further support to the contention of the JAK2 V617F mutation as a marker of increased risk of thrombosis.
|
18616871 |
2008 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
The role of screening for the JAK2 V617F mutation in patients presenting with thrombosis without overt MPD is unclear, but appears justified in cases of idiopathic splanchnic vein thrombosis.
|
19004076 |
2008 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia.
|
18410451 |
2008 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Fourteen (74%) of the 19 patients were heterozygous for JAK2(V617F) but did not meet diagnostic criteria for a MPD at the time of presentation with thrombosis.
|
19046316 |
2008 |
|
Thrombosis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.
|
17392820 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
The results showed that (1) an increased leukocyte count at diagnosis was associated with thrombosis during follow-up ("baseline analysis," relative risk [RR] 2.3, 95% confidence interval [CI] 1.4-3.9, P = .001); (2) hydroxyurea (HU) lowered leukocytosis and reduced the strength of the association between leukocytosis and thrombosis ("time-dependent analysis," RR 1.6, 95% CI 0.9-2.0, not significant [NS]); (3) the association of leukocytosis and thrombosis was more evident in untreated low-risk patients (RR 2.7, 95% CI 1.2-6.4, P = .01) compared with HU-treated high-risk patients (RR 1.6, 95% CI 0.8-3.2, NS); and (4) the presence of JAK2 V617F was not identified as a risk factor for thrombosis during follow-up despite a significant association between the mutation and leukocytosis.
|
17110452 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
|
17920754 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
We investigated the V617F mutation of the JAK2 gene in 295 patients with thrombosis.Only one case was positive.
|
17296594 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
|
17611562 |
2007 |
|
Thrombosis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.
|
17403204 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
To assess the prevalence and clinical implications of this mutation in the setting of intra-abdominal thrombosis, JAK2 V617F genotyping was performed in 42 patients who had catastrophic intra-abdominal thromboses resulting in visceral transplants.
|
17439832 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
|
17229651 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
We studied markers of platelet and coagulation activation in a large cohort of patients with MPD (n = 118) and related this to Janus Kinase 2 (JAK2) V617 F mutation status, a marker of clonality, and the presence of antiphospholipid antibodies (APA), all of which have been associated with thrombosis in MPD.
|
17596137 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Six out of 18 patients (33%) were positive for the JAK2 mutation, and five of these six patients had a history of thrombosis.
|
17703302 |
2007 |
|
Thrombosis
|
0.100 |
GeneticVariation
|
phenotype |
LHGDN |
Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.
|
17057021 |
2006 |